Summary: The Harvard Gazette conducts an interview about the future of psychedelics in psychiatry with Jerrold Rosenbaum, M.D., Director of the Center for the Neuroscience of Psychedelics at Massachusetts General Hospital and Harvard Medical School professor.
“I don’t think it makes sense for psychedelics to continue in Schedule 1,” says Dr. Rosenbaum. “When you talk about harm to self or harm to others, they’re way down the list, below things you can buy in your pharmacy or that your doctor can prescribe. They’re not addictive, though they do create an intense emotional experience that can be distressing if people are not prepared for it or if it’s not done with the right mental set and in the right setting.”
Originally appearing here.
